{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:54:14Z","timestamp":1787849654484,"version":"build-2784847793"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRP-2023-5582"],"award-info":[{"award-number":["IIRP-2023-5582"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.brainres.2024.149018","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T15:55:50Z","timestamp":1716306950000},"page":"149018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Immunotherapeutic approaches for Alzheimer\u2019s disease: Exploring active and passive vaccine progress"],"prefix":"10.1016","volume":"1840","author":[{"given":"Priyanshu","family":"Bhadane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnashish","family":"Roul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sateesh","family":"Belemkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3762-7574","authenticated-orcid":false,"given":"Devendra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2024.149018_b0005","series-title":"Alzheimer's & Dementia : the Journal of the Alzheimer's Association","first-page":"11","article-title":"A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease","author":"Agadjanyan","year":"2015"},{"key":"10.1016\/j.brainres.2024.149018_b0010","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jalz.2015.06.1884","article-title":"A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease","volume":"11","author":"Agadjanyan","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2024.149018_b0015","first-page":"263","volume":"103","author":"Atri","year":"2019","journal-title":"The Alzheimer\u2019s Disease Clinical Spectrum: Diagnosis and Management."},{"key":"10.1016\/j.brainres.2024.149018_b0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jns.2016.01.008","article-title":"Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products","volume":"361","author":"Awasthi","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.brainres.2024.149018_b0025","article-title":"NCT01850238: safety study of AADvac1, a tau peptide-KLH-conjugate active vaccine to treat Alzheimer\u2019s disease","author":"Axon Neuroscience","year":"2013","journal-title":"ClinicalTrials. Gov."},{"key":"10.1016\/j.brainres.2024.149018_b0030","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1523\/JNEUROSCI.22-18-07873.2002","article-title":"Non-Fc-mediated mechanisms are involved in clearance of amyloid-\u03b2 in vivo by immunotherapy","volume":"22","author":"Bacskai","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2024.149018_b0035","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.brainres.2024.149018_b0040","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00401-015-1489-x","article-title":"Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models","volume":"130","author":"Bouter","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.brainres.2024.149018_b0045","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jalz.2015.06.1658","article-title":"Safety of solanezumab in the expedition-ext study up to 2 years in a mild to moderate Alzheimer\u2019s disease population","volume":"11","author":"Carlson","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2024.149018_b0050","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.3233\/JAD-132435","article-title":"Harnessing the immune system for treatment and detection of tau pathology","volume":"40","author":"Congdon","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2024.149018_b0055","first-page":"362","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.brainres.2024.149018_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0227-5","article-title":"Tau passive immunization inhibits not only tau but also A\u03b2 pathology","volume":"9","author":"Dai","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2024.149018_b0065","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.4161\/hv.27882","article-title":"Immunogenicity of DNA-and recombinant protein-based Alzheimer Disease Epitope Vaccines","volume":"10","author":"Davtyan","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.brainres.2024.149018_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0177-y","article-title":"First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer\u2019s disease","volume":"8","author":"Delnomdedieu","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2024.149018_b0075","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1126\/science.1067568","article-title":"Brain to plasma amyloid-\u03b2 efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease","volume":"295","author":"DeMattos","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.brainres.2024.149018_b0080","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1007\/s12011-021-03083-5","article-title":"Centella asiatica alleviates AlCl3-induced cognitive impairment, oxidative stress, and neurodegeneration by modulating cholinergic activity and oxidative burden in rat brain","volume":"200","author":"Firdaus","year":"2022","journal-title":"Biol. Trace Elem. Res."},{"key":"10.1016\/j.brainres.2024.149018_b0085","doi-asserted-by":"crossref","unstructured":"Galimberti, D., Ghezzi, L., Scarpini, E.J.J.o.t.n.s., 2013. Immunotherapy against amyloid pathology in Alzheimer's disease. 333, 50-54.","DOI":"10.1016\/j.jns.2012.12.013"},{"key":"10.1016\/j.brainres.2024.149018_b0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14728214.2016.1146678","article-title":"Emerging amyloid disease-modifying drugs for Alzheimer\u2019s disease","volume":"21","author":"Galimberti","year":"2016","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.brainres.2024.149018_b0095","doi-asserted-by":"crossref","unstructured":"G\u00fcell-Bosch, J., et al., 2016. A\u03b2 immunotherapy for Alzheimer's disease: where are we? Neurodegenerative disease management.","DOI":"10.2217\/nmt-2016-0006"},{"key":"10.1016\/j.brainres.2024.149018_b0100","doi-asserted-by":"crossref","unstructured":"Harris, S.A., Harris, E.A.J.J.o.A.s.D., 2015. Herpes simplex virus type 1 and other pathogens are key causative factors in sporadic Alzheimer\u2019s disease. 48, 319-353. http:\/\/www.clinicaltrials.gov.","DOI":"10.3233\/JAD-142853"},{"key":"10.1016\/j.brainres.2024.149018_b0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","article-title":"Clinical trials of new drugs for Alzheimer disease: a 2020\u20132023 update","volume":"30","author":"Huang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.brainres.2024.149018_b0110","doi-asserted-by":"crossref","unstructured":"Hung, S.-Y., Fu, W.-M.J.J.o.b.s., 2017. Drug candidates in clinical trials for Alzheimer\u2019s disease. 24, 1-12.","DOI":"10.1186\/s12929-017-0355-7"},{"key":"10.1016\/j.brainres.2024.149018_b0115","doi-asserted-by":"crossref","first-page":"19440","DOI":"10.1074\/jbc.M112.346072","article-title":"Trans-cellular propagation of tau aggregation by fibrillar species","volume":"287","author":"Kfoury","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainres.2024.149018_b0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau\u2013tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2024.149018_b0125","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","article-title":"Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead","volume":"148","author":"Kumar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.brainres.2024.149018_b0130","doi-asserted-by":"crossref","first-page":"P331","DOI":"10.1016\/j.jalz.2015.08.153","article-title":"Efficacy and safety of gantenerumab in prodromal Alzheimer\u2019s disease: Results from scarlet road\u2014a global, multicenter trial","volume":"11","author":"Lasser","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2024.149018_b0135","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.brainres.2024.149018_b0140","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/vaccines8030351","article-title":"Yeast-Based A\u03b21-15 vaccine elicits strong immunogenicity and attenuates neuropathology and cognitive deficits in Alzheimer\u2019s disease transgenic mice","volume":"8","author":"Liu","year":"2020","journal-title":"Vaccines."},{"key":"10.1016\/j.brainres.2024.149018_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401-a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2024.149018_b0150","doi-asserted-by":"crossref","first-page":"P610","DOI":"10.1016\/j.jalz.2016.06.1210","article-title":"Exploratory analyses of cognitive effects of crenezumab in a mild alzheimer's disease subpopulation of a randomized, double-blind, placebo-controlled, parallel-group phase 2 study (ABBY)","volume":"12","author":"Mackey","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainres.2024.149018_b0155","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jneuroim.2015.08.008","article-title":"Alzheimer's disease vaccine development: A new strategy focusing on immune modulation","volume":"287","author":"Marciani","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.brainres.2024.149018_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115522","article-title":"Alzheimer\u2019s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs","volume":"211","author":"Monteiro","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainres.2024.149018_b0165","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.brainres.2024.149018_b0170","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial","author":"Novak","year":"2016","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.brainres.2024.149018_b0175","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.brainres.2024.149018_b0180","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1742-4658.2012.08512.x","article-title":"Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles","volume":"279","author":"Pan","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.brainres.2024.149018_b0185","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","article-title":"Tau immunotherapy for Alzheimer's disease","volume":"21","author":"Pedersen","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.brainres.2024.149018_b0190","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000113700","article-title":"Progress in the active immunotherapeutic approach to Alzheimer\u2019s disease: clinical investigations into AN1792-associated meningoencephalitis","volume":"5","author":"Pride","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.brainres.2024.149018_b0195","first-page":"74","article-title":"Alzheimer disease in 2016: Putting AD treatments and biomarkers to the test","volume":"13","author":"Reiman","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.brainres.2024.149018_b0200","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3233\/JAD-2009-1118","article-title":"Anti-amyloid-\u03b2 immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing","volume":"17","author":"Ryan","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.brainres.2024.149018_b0205","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.brainres.2024.149018_b0210","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/cbdd.13965","article-title":"Classification of beta-site amyloid precursor protein cleaving enzyme 1 inhibitors by using machine learning methods","volume":"98","author":"Singh","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.brainres.2024.149018_b0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","article-title":"Immunotherapy for Alzheimer's disease: targeting \u03b2-amyloid and beyond","volume":"11","author":"Song","year":"2022","journal-title":"Transl Neurodegener."},{"key":"10.1016\/j.brainres.2024.149018_b0220","first-page":"130","volume":"109","author":"Srivastava","year":"2021","journal-title":"Viral Vectors as a Promising Nanotherapeutic Approach against Neurodegenerative Disorders."},{"key":"10.1016\/j.brainres.2024.149018_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.brainres.2024.149018_b0230","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.nbd.2005.04.007","article-title":"The F (ab\u2032) 2 fragment of an A\u03b2-specific monoclonal antibody reduces A\u03b2 deposits in the brain","volume":"20","author":"Tamura","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainres.2024.149018_b0235","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2217\/fvl.12.108","article-title":"Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications","volume":"7","author":"Testa","year":"2012","journal-title":"Future Virol."},{"key":"10.1016\/j.brainres.2024.149018_b0240","doi-asserted-by":"crossref","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.brainres.2024.149018_b0245","volume":"Vol.","author":"Tian","year":"2020"},{"key":"10.1016\/j.brainres.2024.149018_b0250","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/vaccines10091527","article-title":"Immunotherapies for Alzheimer\u2019s disease\u2014a review","volume":"10","author":"Valiukas","year":"2022","journal-title":"Vaccines."},{"key":"10.1016\/j.brainres.2024.149018_b0255","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","article-title":"Site-specific UBITh\u00ae amyloid-\u03b2 vaccine for immunotherapy of Alzheimer's disease","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.brainres.2024.149018_b0260","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","article-title":"ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials","volume":"87","author":"Wang","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.brainres.2024.149018_b0265","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","article-title":"The second-generation active A\u03b2 immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects","volume":"31","author":"Wiessner","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2024.149018_b0270","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"The Lancet Neurology."},{"key":"10.1016\/j.brainres.2024.149018_b0275","first-page":"1","volume":"6","author":"Winblad","year":"2014","journal-title":"Active Immunotherapy Options for Alzheimer\u2019s Disease."},{"key":"10.1016\/j.brainres.2024.149018_b0280","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neuron.2014.12.064","article-title":"Immunotherapeutic approaches for Alzheimer\u2019s disease","volume":"85","author":"Wisniewski","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.brainres.2024.149018_b0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","article-title":"Targeting the \u03b2 secretase BACE1 for Alzheimer's disease therapy","volume":"13","author":"Yan","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainres.2024.149018_b0290","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1523\/JNEUROSCI.1676-11.2012","article-title":"Neutralization of soluble, synaptotoxic amyloid \u03b2 species by antibodies is epitope specific","volume":"32","author":"Zago","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainres.2024.149018_b0295","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: Challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899324002725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899324002725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T15:32:57Z","timestamp":1723476777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899324002725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":59,"alternative-id":["S0006899324002725"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2024.149018","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic approaches for Alzheimer\u2019s disease: Exploring active and passive vaccine progress","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2024.149018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149018"}}